The novel coronavirus (SARS-CoV-2) pandemic, dubbed COVID-19, has become one of the most serious challenges for human populations in the vast majority of countries worldwide. Rapid spreading and increased mortality related to it required new approaches to manage epidemic processes on a global scale. One of such approaches was based on analyzing SARS-CoV-2 seroprevalence associated with COVID-19. Our aim was to summarize the results on assessing seroprevalence to the SARS-CoV-2 nucleocapsid antigen (Nc) in residents from 26 regions of the Russian Federation, carried out during the first wave of the COVID-19 epidemic.Materials and methods. Seroprevalence distribution was examined in 26 model regions of the Russian Federation according to the unified method developed by the Rospotrebnadzor with the participation of the Federal State Institution Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Such approach implied formation of a group of volunteer subjects in model geographic region who were tested by ELISA for anti-Nc serum antibody level in peripheral blood. Analyzed primary data obtained in separate regions were either accepted for publication or released.Results. The current paper finalizes the data obtained in all 26 regions of the Russian Federation. The total SARS-CoV-2 seroprevalence was 19.5 (10.0–25.6)% with the maximum and minimum value found in the Kaliningrad Region and the Republic of Crimea, respectively (50.2% vs. 4.3%). A pattern of age-related seroprevalence distribution indicates insignificant predominance of seroprevalence among subjects of 1–17 years old: 22.1 (13.1–31.8)%. Among COVID-19 convalescents positive for SARS-CoV Nc antibodies it reached 60.0 (40.0–73.3)%. The number of contact persons comprised 6285 subjects or 8.5% of total volunteer cohort, with the level of seroprevalence reaching up to 25.3 (17.95–35.8)%. A direct correlation was revealed between levels of seroprevalence in convalescent and contact volunteers. In addition, the reproductive number for SARS-CoV was calculated comprising 5.8 (4.3–8.5) suggesting that one convalescent subject can infect at least 4 healthy individuals. A high level of asymptomatic forms of COVID-19 among seropositive subjects was confirmed empirically comprising up to 93.6 (87.1–94.9)%.Conclusion. A single cross-sectional study performed during 2020 June–August timeframe allowed to assess pattern of sex- and agerelated COVID-19 seroprevalence for general population in 26 Russian Federation regions. The data obtained may serve as a basis for the longitudinal cohort investigation with serial subject sampling. The timing and duration of study will be determined by dynamics of ongoing COVID-19 epidemic.
Результаты. Доля пневмококков в этиологической структуре гнойных бактериальных менингитов (ГБМ) в течение 2010 -2014 годов колебалась в диапазоне 18,4 -24,8% и в среднем составляла 22,1%, уступая только менингококкам (52,2%).
Заболеваемость ПМ в Российской Федерации в 2010 -2014 годах определялась на уровне
Introduction. The coronavirus disease (COVID-19) pandemic was announced by WHO in February 2020. In the Khabarovsk Krai, the first three cases of the disease were diagnosed on March 19, 2020, these cases were imported from Argentina (transit through Italy). The epidemic process of COVID-19 in the Khabarovsk Krai is characterized by a slow increase in the incidence. During the period of time when the SARS-CoV-2 seroprevalence study was conducted the incidence rates varied from 35.9 to 39.1 per 100 thousand population. Within the next 5 weeks the incidence continued to increase, the maximum level was 67.3 per 100 thousand population. A statistically significant decrease in the incidence is noted in the first decade of August. The study of the SARS-CoV-2 seroprevalence among residents of the region was carried out from June 9 to June 21, 2020 during the period of increasing intensity of the epidemic process of COVID-19 infection.Aim. To determine the level and structure of herd immunity to SARS-CoV-2 virus among the population of the Khabarovsk Krai during the period of intensive spread of COVID-19.Materials and methods. The study was conducted as a part of the first stage of a large-scale Rospotrebnadzor project to assess the herd immunity to SARS-CoV-2 virus among the population of the Russian Federation, taking into consideration the protocol recommended by WHO. The selection of volunteers for the study was carried out by the method of questionnaires and randomization by random sampling. The results of a survey of 2675 individuals were included into analysis. The number of volunteers in all age groups was similar.Results. The results of the study showed that the herd immunity to SARS-CoV-2 in the total population of the Khabarovsk Krai was 19.6%. The maximum level of herd immunity was observed in children 14–17 years old (34.4%), children 7–13 years old (24.8%), and people over 70 years (22.6%). The highest level of seropositivity, except for the children and the elderly, was found among educational workers (26.7%). The lowest level of seropositivity was found in the military (8.7%) and the unemployed (8.3%). There were no statistically significant differences in the level of seroprevalence between men and women.Conclusions. The results of the seroepidemiological study demonstrated that in the Khabarovsk Krai, the presence of the contacts with COVID-19 patients is associated with the 1.4-fold increase in the likelihood of the seroconversion. Antibodies were detected in 58.9% of the past COVID-19 cases. In individuals with the previous positive PCR test result, antibodies were detected in 50% of cases. A high rate of asymptomatic infection, up to 93.7%, was observed among seropositive volunteers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.